PSA is a protein made by prostate tissue. A blood test measures its level, but the result alone does not diagnose prostate cancer. PSA can be elevated for reasons other than cancer, and some cancers may occur without a clearly elevated result.
The useful question is not only whether to obtain a test, but how the result would be interpreted and followed up in your circumstances.
Screening and diagnostic testing
Screening checks people without symptoms. A PSA test may also be used in the evaluation of a clinical concern or to monitor an established cancer.
Those purposes are different. A general screening recommendation does not determine how a clinician should investigate symptoms or manage follow-up after treatment.
Tell your clinician why you are considering the test and whether you have previous results.
The USPSTF recommendation
The U.S. Preventive Services Task Force recommends an individual decision about PSA-based screening for men ages 55 through 69, after discussing potential benefits and harms. It recommends against routine PSA-based screening for men 70 and older.
This is one organization's guidance. Other professional groups may use different approaches, including discussion at younger ages for some people.
Family history, ancestry, overall health, and personal preferences belong in the conversation. Ask which recommendation the clinician is using rather than treating a single starting age as universal.
Benefits and possible harms
Screening can help identify some prostate cancers before they cause symptoms. It can also lead to false-positive results, additional tests, and detection of cancers that would not otherwise cause problems during a person's lifetime.
A diagnosis may lead to further decisions about surveillance or treatment, each with its own benefits and burdens.
Ask how you would weigh the possibility of finding a clinically important cancer against the possibility of unnecessary testing or treatment. A screening decision should account for those tradeoffs.
Interpreting an elevated result
There is no single PSA cutoff that reliably divides cancer from noncancer in every person. Benign prostate enlargement, inflammation, and other circumstances can affect the level.
The clinician may consider prior values, repeat testing, examination, additional tests, imaging, or a biopsy as appropriate. An elevated value is the beginning of interpretation rather than a final diagnosis.
Ask which factors could have affected your result and what the proposed next step is intended to clarify.
Preparing for the conversation
Bring prior PSA results with dates, a medication list, family history, and any recent urinary problems or procedures.
Ask whether the test requires particular preparation and whether an existing illness or recent procedure affects timing. Follow the team's instructions rather than stopping medicines or rescheduling on your own.
Confirm who will communicate the result and what happens if it is outside the expected range.
Decide on follow-up before testing
Ask how often screening would be repeated if you choose it, what would trigger further investigation, and who coordinates the next steps.
If you decide against screening for now, you can still discuss symptoms and revisit the decision when circumstances change. Declining a routine test does not mean ignoring a new health concern.
A thoughtful PSA plan includes the reasons for testing, the limitations of the result, and a clear process for follow-up.
